ContraFect Corp.

... ...
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -1.68%130.750.0%$2527.55m
BNGOBioNano Genomics, Inc. 12.14%9.270.0%$1894.87m
GILDGilead Sciences, Inc. -0.19%66.851.0%$661.41m
AMGNAmgen, Inc. 0.55%253.411.3%$563.00m
CRSPCRISPR Therapeutics AG 2.51%189.740.6%$498.16m
ALXNAlexion Pharmaceuticals, Inc. 0.85%159.202.0%$480.87m
REGNRegeneron Pharmaceuticals, Inc. 1.12%541.492.7%$479.22m
NVAXNovavax, Inc. 0.87%123.4692.9%$432.53m
ILMNIllumina, Inc. -0.67%402.173.5%$391.66m
VRTXVertex Pharmaceuticals, Inc. 0.36%239.501.9%$361.72m
SRPTSarepta Therapeutics, Inc. -0.71%96.2313.8%$354.05m
BIIBBiogen, Inc. -0.31%269.291.7%$325.66m
BNTXBioNTech SE 1.00%106.480.0%$302.52m
EXASEXACT Sciences Corp. 0.17%148.3219.6%$240.28m
PACBPacific Biosciences of California, Inc. 1.19%36.747.4%$233.54m

Company Profile

ContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.